.svg)
Cancer-Associated Inflammation and the Blood-Count Ratios That Capture It
Cancer-associated inflammation biomarkers are blood signals that capture how a tumor and the immune system are talking. Cancer often stirs a body-wide inflammatory response that supports tumor growth and spread while straining normal tissues. Measuring these markers gives a real-time readout of that process, beyond what scans alone can show. Many come from the liver as part of the acute-phase response (C-reactive protein, serum amyloid A, fibrinogen), driven by immune messengers released by tumors and immune cells (interleukin-6, TNF-alpha, CXCL chemokines). Others reflect shifts in circulating blood cells mobilized by inflammation (neutrophils, lymphocytes; summarized in ratios like NLR). Some are enzymes and mediators tied to tissue remodeling and clotting (ferritin, lactate dehydrogenase, D-dimer). Together, they mirror the intensity and character of tumor-driven inflammation in the bloodstream, indicating how “hot” the cancer–host interaction is. Tracking them over time can reveal changes in disease activity, show whether treatment is damping inflammatory signaling, and help flag complications related to systemic inflammation.
Why These Composite Ratios Add Prognostic Context
Cancer-associated inflammation markers translate a routine blood count into a systems-level snapshot of immunity, coagulation, and stress biology. Ratios such as the neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio (PLR), and composites like the systemic immune‑inflammation index (SII) and systemic inflammation response index (SIRI) reflect how strongly innate, pro‑tumor inflammation is outweighing lymphocyte‑driven antitumor surveillance.In general populations, NLR often sits around 1–3, PLR around 100–200, SII roughly in the low hundreds, and SIRI around 0.3–1.0; study cut‑points vary by cancer and setting. For prognosis, values toward the lower end of these ranges are usually considered more favorable, while persistently higher values signal greater inflammatory and thrombotic activation.When these indices are low, they typically indicate preserved lymphocyte counts with modest neutrophil and platelet activity—a quieter inflammatory milieu that supports immune surveillance. If very low because neutrophils or platelets are depressed, that can reflect bone‑marrow suppression or viral illness, with symptoms like frequent infections, mouth sores, easy bruising, or heavier menstrual bleeding. Children naturally have lower NLRs (lymphocyte‑predominant), and pregnancy physiologically raises neutrophils, making very low ratios less common.When the indices are high, they point to neutrophilia, monocytosis, and thrombocytosis with relative lymphopenia—an environment linked to tumor growth, cachexia risk, and thrombosis, but also seen with acute infection, major stress, or corticosteroid exposure. People may notice fatigue, fevers, weight loss, or clotting events. Women tend to have slightly higher platelets, nudging PLR upward; pregnancy raises both neutrophils and platelets.Big picture: these markers knit together immunity, hemostasis, metabolism, and endocrine stress. They are not diagnostic but add prognostic context alongside CRP, ESR, albumin, and LDH, helping gauge trajectory, treatment tolerance, and long‑term risks across cancers and cardiovascular disease.
What These Ratios Add and What They Don't Decide
Cancer-Associated Inflammation blood testing provides insight into how your immune system and blood cells interact in the context of cancer risk and overall system health. Chronic inflammation can disrupt energy production, metabolism, cardiovascular function, and immune surveillance, all of which are critical for maintaining resilience against disease. At Superpower, we assess four key biomarkers—NLR (Neutrophil-to-Lymphocyte Ratio), PLR (Platelet-to-Lymphocyte Ratio), SII (Systemic Immune-Inflammation Index), and SIRI (Systemic Inflammation Response Index)—to give a comprehensive view of inflammation linked to cancer biology.NLR and PLR measure the balance between different types of white blood cells and platelets, reflecting how your body responds to stress and inflammation. SII and SIRI are composite indices that integrate neutrophil, lymphocyte, monocyte, and platelet counts, offering a broader picture of immune system activation and inflammatory status. Elevated values in these markers can signal a shift toward a pro-inflammatory state, which is associated with increased cancer risk and progression.Stable, healthy levels of NLR, PLR, SII, and SIRI suggest that your immune system is balanced and not chronically activated. This balance supports tissue repair, immune defense, and cellular stability, reducing the likelihood of inflammation-driven changes that can contribute to cancer development.Interpretation of these biomarkers can be influenced by factors such as acute infections, recent surgery, pregnancy, age, certain medications, and laboratory assay differences. These variables should be considered when evaluating results to ensure an accurate understanding of your inflammation status.
FAQs
This blood test estimates your body’s inflammatory-immune balance, which can influence how cancers start, progress, or respond to therapy. Superpower tests your blood for NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), SII (systemic immune-inflammation index), and SIRI (systemic inflammation response index). These indices come from a standard complete blood count and reflect the interplay between innate immunity (neutrophils, platelets, monocytes) and adaptive immunity (lymphocytes). Higher values generally indicate more systemic inflammation or immune suppression, while lower values suggest a more balanced immune tone. They are not diagnostic of cancer on their own, but they add context to overall disease biology and prognosis when combined with clinical findings.
It gives a quick, objective read on systemic inflammation and immune balance using routine blood counts. In oncology, higher NLR, PLR, SII, and SIRI are associated with worse outcomes in many cancers, while lower values often track with better control. Outside cancer care, these measures can help flag non-specific inflammation that may merit context. Superpower reports NLR, PLR, SII, and SIRI together so you can see how neutrophils, platelets, monocytes, and lymphocytes are interacting. The value is in trend and context, not a single number.
Yes. With Superpower, our team member can organise a blood draw in your home.
There is no universal schedule. These indices are commonly checked whenever routine labs are drawn. During active cancer care or surveillance, they are often reviewed at the same cadence as clinic visits, typically every 4–12 weeks. If you are establishing a baseline, one test when you are well is useful, with repeats to track trend. When you are acutely ill, results can be temporarily distorted, so avoid overinterpreting a single spike. Superpower can align testing with your existing lab timetable.
Many non-cancer factors shift these indices. Acute infections, recent surgery, trauma, or vaccinations can raise neutrophils and platelets. Corticosteroids, chemotherapy, immunotherapy, and radiation change white cell subsets. Iron deficiency or bleeding increases platelets. Smoking, obesity, chronic inflammatory or autoimmune disease, stress, strenuous exercise, dehydration, and pregnancy alter counts. Splenectomy and some hematologic conditions also affect baselines. Because NLR, PLR, SII, and SIRI are ratios built from routine counts, any condition that moves neutrophils, lymphocytes, monocytes, or platelets can move the indices—often transiently.
No special fasting is required. Aim to be well hydrated, avoid unusually strenuous exercise for 24 hours, and try to test when you are not acutely ill. Take medicines as prescribed, but let us know about steroids or other drugs that affect blood counts. If possible, keep the time of day consistent between tests, since white cell counts follow mild circadian patterns. Superpower calculates NLR, PLR, SII, and SIRI from the same tube as your complete blood count, so no extra blood is usually needed.
References
- Cupp, M. A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., & Berlanga-Taylor, A. J. (2020). Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Medicine, 18(1), 360. https://doi.org/10.1186/s12916-020-01817-1
- Templeton, A. J., McNamara, M. G., Seruga, B., Vera-Badillo, F. E., Aneja, P., Ocana, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., Tannock, I. F., & Amir, E. (2014). Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute, 106(6), dju124. https://doi.org/10.1093/jnci/dju124
- Zhong, J. H., Huang, D. H., & Chen, Z. Y. (2017). Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget, 8(43), 75381-75388. https://doi.org/10.18632/oncotarget.18856
- Menyhart, O., Fekete, J. T., & Gyorffy, B. (2024). Inflammation and colorectal cancer: a meta-analysis of the prognostic significance of the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI). International Journal of Molecular Sciences, 25(15), 8441. https://doi.org/10.3390/ijms25158441
- Mei, Z., Shi, L., Wang, B., Yang, J., Xiao, Z., Du, P., Wang, Q., & Yang, W. (2017). Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treatment Reviews, 58, 1-13. https://doi.org/10.1016/j.ctrv.2017.05.005
- Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: a critical update. The Journal of Clinical Investigation, 111(12), 1805-1812. https://doi.org/10.1172/jci18921
.avif)
.svg)
.svg)
